{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:20:32Z","timestamp":1776104432851,"version":"3.50.1"},"reference-count":35,"publisher":"BMJ","issue":"2","funder":[{"name":"Outstanding Young Scholars Support Program from ViiV Care"},{"name":"Kirby Institute"},{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the NSW Ministry of Health"},{"name":"Australian National Health and Medical Research Council","award":["1193955"],"award-info":[{"award-number":["1193955"]}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the MAC AIDS Fund"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2025,6,20]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Pre-exposure prophylaxis (PrEP) usage remains below the Australian 75% coverage target. This study identified preferences for PrEP services shared among subgroups of men who have sex with men (MSM) living in Australia and explored heterogeneity preferences across different age groups and countries of birth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MSM aged&gt;18 years with no prior HIV diagnosis and residing in Australia completed an online discrete choice experiment between May and November 2022. The attributes included type of PrEP, service location, service cost, PrEP side effects, visit frequency and additional services. Participants were recruited through dating apps, Facebook and local MSM community organisations. We used a latent class model (LCM) to explore subgroups with similar preferences for PrEP programmes and a random parameters logit model with interactions to explore heterogeneity preferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 1894 MSM participated, with a mean age of 40 (\u00b112) years. The LCM identified four groups of MSM who shared similar preferences for PrEP services: \u2018Long-acting oral or injectable PrEP from community clinics\u2019 (22% of participants), \u2018Daily oral PrEP from pharmacies\u2019 (5%), \u2018Long-acting oral PrEP from pharmacies\u2019 (52%) and \u2018injectable PrEP from the hospital\u2019 (22%). The group preferring injectable PrEP (22%) preferred accessing PrEP services at hospitals offering sexually transmitted infection testing every 6\u2009months, with a willingness to pay a small fee ($A25). They were willing to endure mild pain at the injection site as a side effect of injectable PrEP. Compared with Australian-born, overseas-born MSM preferred PrEP services offering injectable PrEP. Compared with younger MSM, MSM over 30 years old preferred services offering daily PrEP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is a growing demand for alternatives to oral daily PrEP, with a significant group preferring services including long-acting oral or injectable PrEP and willing to pay a small fee to access it. The majority preferred decentralising access to PrEP through pharmacies. Diverse preferences for PrEP service delivery signify tailored PrEP implementation initiatives to increase PrEP coverage among underserviced populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/sextrans-2025-056507","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:45:30Z","timestamp":1753940730000},"page":"74-81","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Preferences for pre-exposure prophylaxis service package among men who have sex with men in Australia: a discrete choice experiment"],"prefix":"10.1136","volume":"102","author":[{"given":"Warittha","family":"Tieosapjaroen","sequence":"first","affiliation":[{"name":"School of Translational Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9581-1011","authenticated-orcid":false,"given":"Curtis","family":"Chan","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales, Kensington, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doug","family":"Fraser","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales, Kensington, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly E","family":"Green","sequence":"additional","affiliation":[{"name":"Program for Appropriate Technology in Health, Hanoi, Viet Nam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cassell","sequence":"additional","affiliation":[{"name":"Family Health International, Washington, District of Columbia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Murphy","sequence":"additional","affiliation":[{"name":"Australian Research Centre in Sex Health and Society, La Trobe University, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin Robert","family":"Bavinton","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales, Kensington, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather-Marie A","family":"Schmidt","sequence":"additional","affiliation":[{"name":"UNAIDS, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nittaya","family":"Phanuphak","sequence":"additional","affiliation":[{"name":"Institute of HIV Research and Innovation, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-084X","authenticated-orcid":false,"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9026-707X","authenticated-orcid":false,"given":"Weiming","family":"Tang","sequence":"additional","affiliation":[{"name":"Institute of Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5784-7403","authenticated-orcid":false,"given":"Jason J","family":"Ong","sequence":"additional","affiliation":[{"name":"School of Translational Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia"},{"name":"London School of Hygiene and Tropical Medicine, London, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2026021702100700000_102.2.74.1","unstructured":"King J , McManus H , Kwon A , et al . HIV, viral hepatitis and sexually transmissible infections in australia annual surveillance report 2023. Kirby Institute. Available: https:\/\/www.kirby.unsw.edu.au\/research\/reports\/asr2023 [Accessed 2 Jul 2024]."},{"key":"2026021702100700000_102.2.74.2","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S2352-3018(21)00074-6","article-title":"Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study","volume":"8","author":"Grulich","year":"2021","journal-title":"Lancet HIV"},{"key":"2026021702100700000_102.2.74.3","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1016\/S2352-3018(23)00050-4","article-title":"HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study","volume":"10","author":"Callander","year":"2023","journal-title":"Lancet HIV"},{"key":"2026021702100700000_102.2.74.4","first-page":"101071","article-title":"Factors associated with HIV pre-exposure prophylaxis use among Asian men who have sex with men in Sydney and Melbourne, Australia: a cross-sectional study","volume":"46","author":"Tieosapjaroen","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"2026021702100700000_102.2.74.5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"The Lancet"},{"key":"2026021702100700000_102.2.74.6","unstructured":"Therapeutic Goods Administration . Australian public assessment report for tenofovir disoproxil fumarate \/emtricitabine. 2016. Available: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-tenofovir-disoproxil-fumarate-161110.pdf"},{"key":"2026021702100700000_102.2.74.7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/OLQ.0000000000001187","article-title":"Trends in Human Immunodeficiency Virus and Sexually Transmitted Infection Testing Among Gay, Bisexual, and Other Men Who Have Sex With Men After Rapid Scale-up of Preexposure Prophylaxis in Victoria, Australia","volume":"47","author":"Ryan","year":"2020","journal-title":"Sex Transm Dis"},{"key":"2026021702100700000_102.2.74.8","unstructured":"Department of Health-Australian Government . Eighth national HIV strategy 2018-2022. 2024. Available: https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2022\/06\/eighth-national-hiv-strategy-2018-2022.pdf"},{"key":"2026021702100700000_102.2.74.9","unstructured":"The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) National PrEP Guidelines Update . Prevent HIV by prescribing PrEP. Sydney, 2023. Available: https:\/\/ashm.org.au\/resources\/australian-prep-guidelines\/ [accessed 2 Jul 2024]"},{"key":"2026021702100700000_102.2.74.10","unstructured":"Chemist Warehouse . Truvada 300\/200mg tablets 30 - tenofovir + emtricitabine. Available: https:\/\/www.chemistwarehouse.com.au\/buy\/78769\/truvada-300-200mg-tablets-30-tenofovir-emtricitabine [Accessed 16 Oct 2023]."},{"key":"2026021702100700000_102.2.74.11","unstructured":"Bavinton BR , Bushby B , Murphy D , et al . Discussion paper research priorities on implementing cabotegravir for prep in Australia."},{"key":"2026021702100700000_102.2.74.12","unstructured":"Kirby Institute, University of New South Wales . Monitoring HIV pre-exposure prophylaxis (prep) uptake in Australia. Available: https:\/\/www.kirby.unsw.edu.au\/sites\/default\/files\/documents\/Monitoring-HIV-pre-exposure-prohpylaxis-PrEP-uptake-in-Australia_Issue-10.pdf"},{"key":"2026021702100700000_102.2.74.13","unstructured":"Australian Government . Ninth national HIV strategy 2024-2030. Available: https:\/\/www.health.gov.au\/resources\/publications\/ninth-national-hiv-strategy-2024-2030?language=en [Accessed 4 Dec 2024]."},{"key":"2026021702100700000_102.2.74.14","doi-asserted-by":"crossref","first-page":"e788","DOI":"10.1016\/S2352-3018(19)30238-3","article-title":"Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline","volume":"6","author":"Coelho","year":"2019","journal-title":"Lancet HIV"},{"key":"2026021702100700000_102.2.74.15","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0734-2"},{"key":"2026021702100700000_102.2.74.16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/QAI.0000000000003059","article-title":"Preferences for Weight Gain Compared With Other Antiretroviral Therapy Side Effects in People Living With HIV: A Discrete Choice Experiment","volume":"91","author":"Tieosapjaroen","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026021702100700000_102.2.74.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101507","article-title":"Preferences for pre-exposure prophylaxis for HIV: A systematic review of discrete choice experiments","volume":"51","author":"Wulandari","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026021702100700000_102.2.74.18","unstructured":"Chan C , Fraser D , Schmidt H-M , et al . PrEP product awareness, preferences, and past experiences among transgender women and men who have sex with men in asia and australia: the prep appeal study."},{"key":"2026021702100700000_102.2.74.19","doi-asserted-by":"crossref","unstructured":"Hensher DA , Rose JM , Greene WH . Applied choice analysis. 2nd edn. Cambridge: Cambridge University Press, 2015.","DOI":"10.1017\/CBO9781316136232"},{"key":"2026021702100700000_102.2.74.20","doi-asserted-by":"crossref","unstructured":"Tieosapjaroen W , Bavinton B , Schmidt H-M , et al . Preferences for pre-exposure prophylaxis for hiv among men who have sex with men and transgender women in 15 countries in asia and australia: a discrete choice experiment. [Preprint] 2024.","DOI":"10.21203\/rs.3.rs-3410105\/v1"},{"key":"2026021702100700000_102.2.74.21","unstructured":"The World Bank . World bank country and lending groups. 2022. Available: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups [Accessed 15 Aug 2022]."},{"key":"2026021702100700000_102.2.74.22","doi-asserted-by":"publisher","DOI":"10.1002\/hec.984"},{"key":"2026021702100700000_102.2.74.23","unstructured":"World Health Organisation . WHO Implementation Tool for Pre-Exposure Prophylaxis (PrEP) of HIV Infection. 2024. Available: https:\/\/www.who.int\/tools\/prep-implementation-tool [Accessed 21 Nov 2024]."},{"key":"2026021702100700000_102.2.74.24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"key":"2026021702100700000_102.2.74.25","unstructured":"MELBOURNE RAPID HIV TESTING . How much does it cost. Available: https:\/\/rapidhivtesting.com.au\/how-much-does-it-cost\/ [Accessed 3 Jul 2024]."},{"key":"2026021702100700000_102.2.74.26","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1016\/S2468-2667(23)00105-6","article-title":"Improving access to oral pre-exposure prophylaxis for HIV among international migrant populations","volume":"8","author":"Tieosapjaroen","year":"2023","journal-title":"Lancet Public Health"},{"key":"2026021702100700000_102.2.74.27","unstructured":"Australian Government . HIV taskforce report. 2023. Available: https:\/\/www.health.gov.au\/resources\/publications\/hiv-taskforce-report?language=en [Accessed 22 Nov 2024]."},{"key":"2026021702100700000_102.2.74.28","doi-asserted-by":"publisher","DOI":"10.1071\/SH18065"},{"key":"2026021702100700000_102.2.74.29","unstructured":"Health Equity Matters . 2024\/25 federal budget analysis. Available: https:\/\/assets.healthequitymatters.org.au\/wp-content\/uploads\/2024\/05\/16053430\/2024-2025-Federal-Budget-Analysis-Health-Equity-Matters.pdf"},{"key":"2026021702100700000_102.2.74.30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10461-021-03344-3","article-title":"Preferences for Current and Future PrEP Modalities Among PrEP-Experienced Gay and Bisexual Men in Australia","volume":"26","author":"Chan","year":"2022","journal-title":"AIDS Behav"},{"key":"2026021702100700000_102.2.74.31","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/S2214-109X(23)00536-3","article-title":"Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis","volume":"12","author":"Zhao","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2026021702100700000_102.2.74.32","unstructured":"Tembo A . Early learning from delivery of PrEP choice in AXIS. AIDS2024; Munich, Germany, 2024."},{"key":"2026021702100700000_102.2.74.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"2026021702100700000_102.2.74.34","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-018-0954-6"},{"key":"2026021702100700000_102.2.74.35","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0181-7"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2025-056507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T10:10:34Z","timestamp":1771323034000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2025-056507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,17]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/sextrans-2025-056507"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2025-056507","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}